INVOLVEMENT OF CYP2D6, CYP3A4, AND OTHER CYTOCHROME-P-450 ISOZYMES IN N-DEALKYLATION REACTIONS

被引：80

作者：

COUTTS, RT ^{[1
]}

SU, P ^{[1
]}

BAKER, GB ^{[1
]}

机构：

[1] UNIV ALBERTA,DEPT PSYCHIAT,EDMONTON,AB,CANADA

来源：

JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS | 1994年 / 31卷 / 04期

关键词：

METABOLIC N-DEALKYLATION; CYTOCHROME P-450 ISOZYMES; CYP2D6; CYP3A ISOZYMES; DRUG METABOLISM;

D O I：

10.1016/1056-8719(94)90001-9

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Metabolic N-dealkylation is a commonly observed biotransformation with tertiary and secondary amine drugs and related N-alkylated amides, but surprisingly little is known about the cytochrome P-450 isozymes involved in these dealkylation reactions. In this review, evidence is provided that supports the involvement of various P-450 isozymes, but especially CYP3A4 and other isozymes of the CYP3A subfamily. Although CYP2D6 is generally not considered to be capable of catalyzing the N-dealkylation of basic drugs, some examples of the involvement of this important isozyme in N-dealkylation reactions are identified. Procedures used to identify individual P-450 isozymes involved in N-dealkylation reactions are discussed.

引用

收藏

页码：177 / 186

页数：10

相关论文

共 79 条

[11]

BOTSCH S, 1993, MOL PHARMACOL, V43, P120

[12] ENANTIOSELECTIVE AMITRIPTYLINE METABOLISM IN PATIENTS PHENOTYPED FOR 2 CYTOCHROME-P450 ISOZYMES [J].

BREYERPFAFF, U ;

PFANDL, B ;

NILL, K ;

NUSSER, E ;

MONNEY, C ;

JONZIERPEREY, M ;

BAETTIG, D ;

BAUMANN, P .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 1992, 52 (04) :350-358

[13] CATALYTIC ACTIVITIES OF HUMAN LIVER CYTOCHROME-P-450-IIIA4 EXPRESSED IN SACCHAROMYCES-CEREVISIAE [J].

BRIAN, WR ;

SARI, MA ;

IWASAKI, M ;

SHIMADA, T ;

KAMINSKY, LS ;

GUENGERICH, FP .

BIOCHEMISTRY, 1990, 29 (51) :11280-11292

[14] IMIPRAMINE DEMETHYLATION AND HYDROXYLATION - IMPACT OF THE SPARTEINE OXIDATION PHENOTYPE [J].

BROSEN, K ;

OTTON, SV ;

GRAM, LF .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 1986, 40 (05) :543-549

[15] ROLE OF P450IID6, THE TARGET OF THE SPARTEINE-DEBRISOQUIN OXIDATION POLYMORPHISM, IN THE METABOLISM OF IMIPRAMINE [J].

BROSEN, K ;

ZEUGIN, T ;

MEYER, UA .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 1991, 49 (06) :609-617

[16] QUINIDINE INHIBITS THE 2-HYDROXYLATION OF IMIPRAMINE AND DESIPRAMINE BUT NOT THE DEMETHYLATION OF IMIPRAMINE [J].

BROSEN, K ;

GRAM, LF .

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1989, 37 (02) :155-160

[17] COMPARATIVE-STUDIES OF N-HYDROXYLATION AND N-DEMETHYLATION BY MICROSOMAL CYTOCHROME-P-450 [J].

BURSTYN, JN ;

ISKANDAR, M ;

BRADY, JF ;

FUKUTO, JM ;

CHO, AK .

CHEMICAL RESEARCH IN TOXICOLOGY, 1991, 4 (01) :70-76

[18] HUMAN CYTOCHROME P-450PA (P-450IA2), THE PHENACETIN O-DEETHYLASE, IS PRIMARILY RESPONSIBLE FOR THE HEPATIC 3-DEMETHYLATION OF CAFFEINE AND N-OXIDATION OF CARCINOGENIC ARYLAMINES - (AROMATIC-AMINES HETEROCYCLIC AMINES CARCINOGEN METABOLISM) [J].

BUTLER, MA ;

IWASAKI, M ;

GUENGERICH, FP ;

KADLUBAR, FF .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (20) :7696-7700

[19] ELECTROCHEMISTRY OF NORCOCAINE NITROXIDE AND RELATED-COMPOUNDS - IMPLICATIONS FOR COCAINE HEPATOTOXICITY [J].

CHARKOUDIAN, JC ;

SHUSTER, L .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1985, 130 (03) :1044-1051

[20] THE ROLE OF INDIVIDUAL HUMAN CYTOCHROMES-P450 IN DRUG-METABOLISM AND CLINICAL-RESPONSE [J].

CHOLERTON, S ;

DALY, AK ;

IDLE, JR .

TRENDS IN PHARMACOLOGICAL SCIENCES, 1992, 13 (12) :434-439

← 1 2 3 4 5 6 7 8 →